Valneva SE (VALN) News
Follow Valneva SE (VALN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Valneva Maintains 2026 Revenue Guidance After First-Half Sales Decline
Valneva reported first-half 2026 product sales of €64 million, down from €91 million a year earlier, and maintained its 2026 guidance for product sales and total revenue.
EQUITY | Oct 14, 2026, 10:05 AM UTC
L
University of Michigan sentiment falls to 51 in early August
The University of Michigan's consumer sentiment index declined to 51 in early August from 55.2 in the previous month, missing market estimates of 54.5.
EARNINGS | Aug 14, 2026, 04:02 PM UTC
M
Pfizer (PFE) and Valneva (VALN) EMA validates Lyme vaccine MAA
EMA validates the marketing authorization application for PF-07307405, based on the Phase 3 VALOR trial in more than 9,400 participants aged five years and older, reporting more than 70% efficacy and no safety concerns.
REGULATION | Aug 14, 2026, 09:17 AM UTC
L
Valneva affirms FY2026 sales guidance at $169.795M-$187.360M
Valneva affirms its FY2026 sales outlook at $169.795 million-$187.360 million versus a $171.630 million estimate.
EARNINGS | Aug 13, 2026, 02:20 PM UTC
L
Valneva reports H1 2026 product sales €64.0M, net loss €63.3M
Valneva reports H1 2026 total product sales of €64.0 million, down from €91.0 million YoY, and a net loss widening to €63.3 million from €20.8 million YoY, while reaffirming full-year guidance of €135–150 million.
EARNINGS | Aug 13, 2026, 05:11 AM UTC